The latest lung squamous cancer targeted agents are PD-1 immune agents such as K and O drugs, EGFR, ALK, ROS1 positive targeted agents such as gefitinib, erlotinib, erlotinib and crizotinib. First-generation TKl or ALK, ROS1-targeted drugs that failed treatment: oxitinib and ceritinib, erlotinib, and enzatinib, and vascular-targeted drugs, such as apatinib and anlotinib. All of the above targeted drugs have the following side effects, such as rash, weakness, heart failure due to elevated cardiac enzymes, liver and kidney function impairment, hypothyroidism, arterial thrombosis, nausea, vomiting, diarrhea, loss of appetite, elevated urine protein, elevated blood pressure, hemoptysis, blood in stool, decreased white blood cell platelets, and angioma.